This article is more than 5 years old. Information may no longer be current.

Lupin receives FDA approval for generic Lexapro tablets

Drugmaker Lupin Pharmaceuticals Inc. announced today that the company has received FDA approval to market a generic version of Forest Laboratories’ antidepressant Lexapro.

Escitalopram Tablets (escitalopram oxalate) 5 mg, 10 mg and 20 mg are indicated for acute and maintenance treatment of major depressive disorder in adults and adolescents aged 12 to 17 years. The drug is also approved for treatment of general anxiety disorder in adults.

According to Lupin, Lexapro Tablets had annual sales in the United States of about $2.7 billion for the 12 months ending in June. Headquartered in Baltimore, Lupin is the fifth largest generics player in the United States, with a 5.5% share by prescriptions, according to IMS Health.